Skip to main page content

Michael Ip

Keynote Speaker
Participates in 12 items

Michael S. Ip, MD

 

Michael S. Ip, MD, is Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles.  He is a member of the Doheny Eye Institute and currently serves as the Medical Director of the Doheny Image Reading Center.  Prior to June 2016, Dr. Ip was on faculty at the University of Wisconsin School of Medicine and Public Health in Madison, WI and was a co-director of the Fundus Photograph Reading Center at the University of Wisconsin.  He also served as Director of the Retina Service at the William S. Middleton Memorial Veterans Hospital in Madison, WI. Dr. Ip received his medical degree from New York University and completed his internship at Lenox Hill Hospital, both in New York, New York. He completed his residency at the University of Pittsburgh School of Medicine in Pennsylvania followed by a fellowship in vitreoretinal surgery at the New England Eye Center, Tufts University, in Boston, Massachusetts.

 

Dr. Ip’s research focuses on the design and conduct of clinical trials investigating treatments for diabetic retinopathy, AMD, and retinal venous occlusive disease. Previously as Co-Director of the Fundus Photograph Reading Center, he has assisted with the collection, analysis, and dissemination of important secondary outcomes in numerous industry and NIH-funded ophthalmic clinical trials. As a clinical site investigator, he has served as the Principal Investigator on over 17 clinical trials. He has also served as the protocol chair for the clinical trial conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema and as the National Principal Investigator for the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study. In 2003, Dr. Ip and colleagues received an award from the NEI to conduct the SCORE Study.  In 2013, this group received funding from the NEI to conduct the SCORE2 Study.  This avenue of research continues in his role as the Medical Director of the Doheny Image Reading Center.

 

He has authored more than 120 peer-reviewed articles, 25 book chapters, and more than 70 abstracts on these topics as well as has given many national and international presentations. Dr. Ip is also a reviewer for the following six journals: Ophthalmic Surgery and Lasers, Investigative Ophthalmology and Visual Science, American Journal of Ophthalmology, Retina, and Ophthalmology. He is as well a former Associate Editor for Archives of Ophthalmology. FurthermoreDr. Ip has been recognized with several honors, including the Senior Achievement Award and the Leadership Development Program Award, both from the American Academy of Ophthalmology.

Financial disclosure: Dr. Ip has/had an affiliation (financial or otherwise) with a commercial organization:

1.  Aerie

2.  Allergan

3.  Alimera

4.  Amgen

5.  Apellis

6.  Cell Lineage Therapeutics

7.  Clearside

8.  Genentech

9.  Novartis

10. OccuRX

11. Regeneron

12. RegenexBio 

  

 

 

Sessions in which Michael Ip participates

Saturday 11 June, 2022

Time Zone: (GMT-04:00) Atlantic Time (Canada)
10:45 AM
10:45 AM - 12:15 PM | 1 hour 30 minutes
Retina

Learning ObjectivesAt the end of this session, participants will be able to:Assess and manage vitreoretinal lymphomaDescribe the choroidal changes in the treatment of diabetic retinopathyIntegrate new concepts in retinal detachment managementCanMEDS Roles: Medical Expert, Scholar 

1:30 PM
1:30 PM - 3:00 PM | 1 hour 30 minutes
Retina

Learning ObjectivesAt the end of this session, participants will be able to:Manage macular edema secondary to retinal vein occlusionDescribe management of peripapillary choroidal melanomasIntegrate new concepts in retinal detachment managementCanMEDS Roles: Medical Expert, Scholar

Sunday 12 June, 2022

Time Zone: (GMT-04:00) Atlantic Time (Canada)
6:30 AM
6:30 AM - 8:00 AM | 1 hour 30 minutes
Co-Developed Symposium

LEARNING OBJECTIVESAt the end of this symposium, participants will be able to:Identify the critical unmet needs in neovascular AMD and DME managementDemonstrate a comprehensive understanding of new therapeutic agents and their mechanism of action in nAMD and DME managementExamine how to incorporate new therapeutic options into current management strategies for patients with nAMD and DMEApply new insights from multi-modal imagin...

6:40 AM
6:40 AM - 6:52 AM | 12 minutes
RetinaCo-Developed Symposium
6:50 AM
6:52 AM - 6:57 AM | 5 minutes
RetinaCo-Developed Symposium
7:05 AM
7:07 AM - 7:10 AM | 3 minutes
RetinaCo-Developed Symposium
7:10 AM
7:10 AM - 7:25 AM | 15 minutes
RetinaCo-Developed Symposium
7:40 AM
7:40 AM - 7:50 AM | 10 minutes
RetinaCo-Developed Symposium
8:00 AM
8:00 AM - 10:00 AM | 2 hours
Current Concepts

Learning ObjectivesAt the end of this session, participants will be able to:Recognize features of optic neuritis requiring prompt investigation and more aggressive managementDescribe the challenges of and barriers to delivering eye care to indigent populationsRecognize features of optic neuritis requiring prompt investigation and more aggressive management

8:10 AM
8:12 AM - 8:22 AM | 10 minutes
Current ConceptsRetina